164 related articles for article (PubMed ID: 36478896)
1. Role of SHP2/PTPN11 in the occurrence and prognosis of cancer: A systematic review and meta-analysis.
Li S; Wang X; Li Q; Li C
Oncol Lett; 2023 Jan; 25(1):19. PubMed ID: 36478896
[TBL] [Abstract][Full Text] [Related]
2. SHP2 is involved in the occurrence, development and prognosis of cancer.
Li S; Qu J; Wang X; Zou Q; Li C
Oncol Lett; 2023 Sep; 26(3):393. PubMed ID: 37600341
[TBL] [Abstract][Full Text] [Related]
3. Activating mutations of the noonan syndrome-associated SHP2/PTPN11 gene in human solid tumors and adult acute myelogenous leukemia.
Bentires-Alj M; Paez JG; David FS; Keilhack H; Halmos B; Naoki K; Maris JM; Richardson A; Bardelli A; Sugarbaker DJ; Richards WG; Du J; Girard L; Minna JD; Loh ML; Fisher DE; Velculescu VE; Vogelstein B; Meyerson M; Sellers WR; Neel BG
Cancer Res; 2004 Dec; 64(24):8816-20. PubMed ID: 15604238
[TBL] [Abstract][Full Text] [Related]
4. Prognostic significance of SHP2 (PTPN11) expression in solid tumors: A meta-analysis.
Zhou J; Guo H; Zhang Y; Liu H; Dou Q
PLoS One; 2022; 17(1):e0262931. PubMed ID: 35061863
[TBL] [Abstract][Full Text] [Related]
5. The tumor suppressor role of Src homology phosphotyrosine phosphatase 2 in hepatocellular carcinoma.
Jiang C; Hu F; Tai Y; Du J; Mao B; Yuan Z; Wang Y; Wei L
J Cancer Res Clin Oncol; 2012 Apr; 138(4):637-46. PubMed ID: 22228034
[TBL] [Abstract][Full Text] [Related]
6. Noonan syndrome-associated SHP2/PTPN11 mutants cause EGF-dependent prolonged GAB1 binding and sustained ERK2/MAPK1 activation.
Fragale A; Tartaglia M; Wu J; Gelb BD
Hum Mutat; 2004 Mar; 23(3):267-77. PubMed ID: 14974085
[TBL] [Abstract][Full Text] [Related]
7. Association of nuclear localization of SHP2 and YAP1 with unfavorable prognosis in non-small cell lung cancer.
Chen MJ; Wang YC; Wu DW; Chen CY; Lee H
Pathol Res Pract; 2019 Apr; 215(4):801-806. PubMed ID: 30685130
[TBL] [Abstract][Full Text] [Related]
8. Targeting protein tyrosine phosphatase SHP2 for the treatment of PTPN11-associated malignancies.
Yu B; Liu W; Yu WM; Loh ML; Alter S; Guvench O; Mackerell AD; Tang LD; Qu CK
Mol Cancer Ther; 2013 Sep; 12(9):1738-48. PubMed ID: 23825065
[TBL] [Abstract][Full Text] [Related]
9. Polyphyllin D Shows Anticancer Effect through a Selective Inhibition of Src Homology Region 2-Containing Protein Tyrosine Phosphatase-2 (SHP2).
Kwon SJ; Ahn D; Yang HM; Kang HJ; Chung SJ
Molecules; 2021 Feb; 26(4):. PubMed ID: 33562835
[TBL] [Abstract][Full Text] [Related]
10. Gain-of-function mutations of Ptpn11 (Shp2) cause aberrant mitosis and increase susceptibility to DNA damage-induced malignancies.
Liu X; Zheng H; Li X; Wang S; Meyerson HJ; Yang W; Neel BG; Qu CK
Proc Natl Acad Sci U S A; 2016 Jan; 113(4):984-9. PubMed ID: 26755576
[TBL] [Abstract][Full Text] [Related]
11. Structure, function, and pathogenesis of SHP2 in developmental disorders and tumorigenesis.
Huang WQ; Lin Q; Zhuang X; Cai LL; Ruan RS; Lu ZX; Tzeng CM
Curr Cancer Drug Targets; 2014; 14(6):567-88. PubMed ID: 25039348
[TBL] [Abstract][Full Text] [Related]
12. Modeling (not so) rare developmental disorders associated with mutations in the protein-tyrosine phosphatase SHP2.
Solman M; Woutersen DTJ; den Hertog J
Front Cell Dev Biol; 2022; 10():1046415. PubMed ID: 36407105
[TBL] [Abstract][Full Text] [Related]
13. Expression and clinical significance of SHP2 in gastric cancer.
Dong S; Li FQ; Zhang Q; Lv KZ; Yang HL; Gao Y; Yu JR
J Int Med Res; 2012; 40(6):2083-9. PubMed ID: 23321164
[TBL] [Abstract][Full Text] [Related]
14. Discovery of novel furanylbenzamide inhibitors that target oncogenic tyrosine phosphatase SHP2 in leukemia cells.
Raveendra-Panickar D; Finlay D; Layng FI; Lambert LJ; Celeridad M; Zhao M; Barbosa K; De Backer LJS; Kwong E; Gosalia P; Rodiles S; Holleran J; Ardecky R; Grotegut S; Olson S; Hutchinson JH; Pasquale EB; Vuori K; Deshpande AJ; Cosford NDP; Tautz L
J Biol Chem; 2022 Jan; 298(1):101477. PubMed ID: 34896393
[TBL] [Abstract][Full Text] [Related]
15. T cell-specific constitutive active SHP2 enhances T cell memory formation and reduces T cell activation.
Cammann C; Israel N; Frentzel S; Jeron A; Topfstedt E; Schüler T; Simeoni L; Zenker M; Fehling HJ; Schraven B; Bruder D; Seifert U
Front Immunol; 2022; 13():958616. PubMed ID: 35983034
[TBL] [Abstract][Full Text] [Related]
16. [The Biological Function of SHP2 in Human Disease].
Li SM
Mol Biol (Mosk); 2016; 50(1):27-33. PubMed ID: 27028808
[TBL] [Abstract][Full Text] [Related]
17. Medicinal chemistry strategies for the development of protein tyrosine phosphatase SHP2 inhibitors and PROTAC degraders.
Tang K; Jia YN; Yu B; Liu HM
Eur J Med Chem; 2020 Oct; 204():112657. PubMed ID: 32738411
[TBL] [Abstract][Full Text] [Related]
18. Induction of a tumor-associated activating mutation in protein tyrosine phosphatase Ptpn11 (Shp2) enhances mitochondrial metabolism, leading to oxidative stress and senescence.
Zheng H; Li S; Hsu P; Qu CK
J Biol Chem; 2013 Sep; 288(36):25727-25738. PubMed ID: 23884424
[TBL] [Abstract][Full Text] [Related]
19. The tyrosine phosphatase Shp2 (PTPN11) in cancer.
Chan G; Kalaitzidis D; Neel BG
Cancer Metastasis Rev; 2008 Jun; 27(2):179-92. PubMed ID: 18286234
[TBL] [Abstract][Full Text] [Related]
20. A cellular target engagement assay for the characterization of SHP2 (PTPN11) phosphatase inhibitors.
Romero C; Lambert LJ; Sheffler DJ; De Backer LJS; Raveendra-Panickar D; Celeridad M; Grotegut S; Rodiles S; Holleran J; Sergienko E; Pasquale EB; Cosford NDP; Tautz L
J Biol Chem; 2020 Feb; 295(9):2601-2613. PubMed ID: 31953320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
